Here’s why Moderna is surging (January 6)

Traders Union
All News
Financial News
Moderna Surges 10.85% Today

Highlights

Moderna's mNEXSPIKE product rapidly became a leading choice in the U.S. retail COVID-19 market following its 2025 launch, signaling robust demand.
Moderna has reinforced global partnerships to improve revenue visibility for its mRNA vaccine products, strengthening its commercial outlook.
Recent developments shift market attention toward product adoption rates and the effectiveness of Moderna's strategic growth initiatives.

Revenue visibility improves as new vaccine launches drive sentiment

Moderna's mNEXSPIKE product has quickly become a leading option in the U.S. retail COVID-19 market following its 2025 launch, reflecting strong commercial progress in its core vaccine portfolio. The company has also strengthened global partnerships to enhance revenue visibility for its mRNA vaccine products. These recent developments increase focus on product adoption and strategic growth initiatives.

Anton Kharitonov, expert at Traders Union, notes that Moderna’s price is stretched well above all major moving averages. He sees the sharp upside move as technically strong, but questions the sustainability given several overbought oscillators. Kharitonov highlights that momentum remains positive, yet warns that a daily ADX just under 25 and intense volatility signal caution. He also points to an aggressive gap at the open, which often invites profit-taking after extended runs. "Despite strong vaccine news and bullish signals, I see significant near-term risk of a technical pullback toward $31.00 if buying power wanes."

Viktoras Karapetjanc, expert at Traders Union, believes Moderna’s commercial progress with mNEXSPIKE reflects robust demand and growing investor confidence. He notes that strengthened global partnerships add visibility to future revenue streams and further support the underlying fundamental story. Karapetjanc observes that the bullish structure remains intact above key supports, with price action confirming strong market appetite. "Further growth is expected as Moderna’s product adoption accelerates and the market offers multiple bullish setups above $36.00."

Overbought signals emerge as strong momentum clashes with resistance

The closest dynamic support is in the $30.09 area based on the Ichimoku kijun, while the next possible resistance sits near the recent high or the psychological $36.00 — $36.25 zone. Momentum readings remain distinctly bullish with MACD and ADX both favoring further upside, though the ADX level on daily is just below the classic 25 trend confirmation threshold. RSI is at 68.93, CCI is overbought at 161.36, and Stoch RSI is neutral on the day but points to overbought in most intraday timeframes. BBP is firmly in overbought territory, signaling that buyers dominate short-term action. The Awesome Oscillator is neutral, not providing additional trend confirmation. The stock leaped $3.49 higher, up 10.85% with a clear gap at the open and is currently trading near the upper end of today's range, underscoring high intraday volatility and persistent strength toward the session highs. Despite the dominant upward momentum, multiple oscillators indicating overbought conditions highlight some risk of near-term exhaustion, so there is a notable divergence between sustained momentum and short-term oscillator signals.

Last time, analysts noted that bullish momentum dominated as the price traded well above all major moving averages and technical indicators such as MACD and ADX confirmed a strong upward trend. Overbought signals from oscillators tempered by continued buyer interest indicated that high intraday volatility and sustained strength were likely to persist, with short-term support found near dynamic indicator levels and resistance around prior local highs.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.